Table 1 Overview of participants, their health status, the derived cultures and the outcome of the metagenomic profiling of the original fecal samplea

From: Targeted isolation of Methanobrevibacter strains from fecal samples expands the cultivated human archaeome

PARTICIPANTS

CULTIVATION

METAGENOMIC PROFILING

#

Disorder

breath CH4 [ppm]

Enrichment cultures (medium/syntroph)

Predominant archaeon

CH4 [%]

Bacteria [%]

Archaea [%]

M. smithii [% of archaea]

Cand. M. intestini [% of archaea]

P15

None

30

P15 (MpT1 / B. t.)

M. smithii

16.5

99.76

0.24

88.8

5.1

P15 (MS / B. t.)

M. smithii

20.7

P20

None

17

P20 (MS / B. t.)

M. smithii

22.2

99.82

0.18

76.5

3.5

P31

None

70

P31 (MS / B. t.)

M. smithii

23.6

n.a.

P32

None

44

P32 (MS / B. t.)

M. smithii + DS

23.4

99.87

0.13

90.8

6.3

P45

None

16

P45 (MS / B. t.)

Cand. M. intestini

23.8

99.84

0.16

7.9

79.5

P46

None

21

P46 (MpT1 / B. t.)

Cand. M. intestini

24.2

99.49

0.51

8.6

89.9

P51

None

28

P51 (MS / B. t.)

Cand. M. intestini

5.5

99.96

0.04

6.5

83.1

P82

None

22

P82 (MpT1)

Cand. M. intestini

25.2

n.a.

P34

CD, flatulence, abdominal pain

22

n.a.

n.a.

n.a.

n.a.

P48

IBS

26

P48 (MpT1 / B. t.)

M. smithii

22.2

99.66

0.34

94.0

5.3

P61

IBS, Lactose I, SIBO

21

P61 (MpT1)

M. smithii

23

n.a.

P66

Lactose I

55

P66 (MS / B. t.)

M. smithii Cand. M. intestini

21.8

99.16

0.84

94.6

4.8

P85

CD

6

n.a.

n.a.

n.a.

99.99

0.01

0

0

P86

Lactose I

13

P86 (MS / B. t.)

Cand. M. intestini + DS

22.4

99.99

0.01

63.9

3.8

P86 (MS)

M. smithii + DS

21.1

P88

IBS, lactose I, fructose I

8

P88 (MS)

M. smithii

22.3

99.87

0.13

72.4

3.8

P89

IBS, lactose I, pancreatic inflam.

10

P89 (MS / B. t.)

Cand. M. intestini

21.2

99.78

0.22

5.6

88.6

  1. aCD: Crohn’s Disease, IBS: Inflammatory Bowel Syndrome, Lactose I: Lactose intolerance, Fructose I: Fructose intolerance, SIBO: Small Intestinal Bacterial Overgrowth. CH4 analysis indicated the presence of methanogenic archaea in the participant’s microbiome. Derived cultures are labeled according to the participant number, the culture medium (MS: MS medium, MpT1: MpT1 medium), and the supplementation with B. thetaiotaomicron (B.t.). Additional genomes acquired through dilution series are annotated with + DS. The predominant archaeon as detected through Nanopore sequencing is given, and the outcome of the CH4 measurement of the cultures 10 days of incubation at 37 °C. The metagenomic information of the original fecal sample was analyzed with respect to the relative abundance of Bacteria, Archaea, M. smithii and Cand. M. intestini.